| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
The Oncologist |
Myelodysplastic Syndromes (MDS) |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Newly revised 2023 MDS response criteria |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| What causes aplastic anaemia? |
|
Leukemia |
Aplastic Anemia |
| Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
| Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
|
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
